RAS Oncology & Therapy最新文献

筛选

英文中文

Challenges and Opportunities to Access Innovation in Latin America: The Case of Combination Therapies for Multiple Myeloma 拉丁美洲获得创新的挑战和机遇:多发性骨髓瘤联合治疗的案例

RAS Oncology & Therapy Pub Date : 1900-01-01 DOI: 10.51520/2766-2586-15

Cristina Gutiérrez Delgado, V. Abello, Martha Alvarado, Daniel Lew, D. Londoño, E. McElwee, Mariana Rico Restrepo, N. Schutz, S. Stefani, Â. Maiolino

{"title":"Challenges and Opportunities to Access Innovation in Latin America: The Case of Combination Therapies for Multiple Myeloma","authors":"Cristina Gutiérrez Delgado, V. Abello, Martha Alvarado, Daniel Lew, D. Londoño, E. McElwee, Mariana Rico Restrepo, N. Schutz, S. Stefani, Â. Maiolino","doi":"10.51520/2766-2586-15","DOIUrl":"https://doi.org/10.51520/2766-2586-15","url":null,"abstract":"Purpose: To address the barriers limiting access to combination therapies (CTs) in Latin America (LA), specifically for patients with multiple myeloma (MM), alongside a roadmap to address them.\u0000\u0000Methods: A panel of LA experts was provided with relevant questions to address in a multi-day conference. Responses were discussed and edited by the panel through numerous drafts and discussions until consensus was achieved.\u0000\u0000Results: The authors identified challenges in CT access in MM in LA and proposed suggestions to address these, including health technology assessment frameworks that assign value to each constituent, adapted legal structures enabling collaborative pricing negotiations, and innovative pricing and contracting mechanisms. These challenges and suggestions apply to CT for other oncologic diseases.\u0000\u0000Conclusion: Increasing CT access demands concerted efforts from all stakeholders. As regulatory and pricing barriers persist, a great need exists to increase CT access in LA. These suggestions can serve as a roadmap for CT adoption in other countries. Keywords: Latin America; combination therapy; multiple myeloma; value attribution, HTA, access, pricing; reimbursement.","PeriodicalId":184234,"journal":{"name":"RAS Oncology & Therapy","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115291363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adopting Molecular Testing for Solid Tumors in Latin America: Challenges and Opportunities 拉丁美洲实体肿瘤分子检测:挑战与机遇

RAS Oncology & Therapy Pub Date : 1900-01-01 DOI: 10.51520/2766-2586-16

L. Araújo, F. Costa, R. Parra, F. Pitoia, M. Rico-Restrepo, Marcos Santos, Luiz Eduardo Pino

{"title":"Adopting Molecular Testing for Solid Tumors in Latin America: Challenges and Opportunities","authors":"L. Araújo, F. Costa, R. Parra, F. Pitoia, M. Rico-Restrepo, Marcos Santos, Luiz Eduardo Pino","doi":"10.51520/2766-2586-16","DOIUrl":"https://doi.org/10.51520/2766-2586-16","url":null,"abstract":"Introduction: The advent of precision medicine, including molecular testing (MT), has revolutionized the cancer care landscape and may provide a path forward in the sustainability of cancer care.\u0000\u0000Methods: Americas Health Foundation (AHF) identified a panel of seven experts in MT with backgrounds in clinical oncology, molecular pathology, and bioethics from Argentina, Brazil, and Colombia. They convened for a three-day virtual meeting on November 10-12, 2021, to discuss the need for widespread access and adoption of MT for solid tumors in Latin America (LA).\u0000\u0000Results: The authors identified challenges in MT access in molecular medicine (MM) in LA and proposed suggestions to manage them. Development and implementation of human talent, infrastructure, and policy strategies are essential to provide MT in LA. This review outlines the substantial challenges faced by countries in LA to the widespread adoption of MT in oncology and provides recommendations on overcoming them.\u0000\u0000Conclusions: Despite the many advantages of MT for solid tumors, the challenges for implementation in LA healthcare systems are sizable and multidimensional. These include regional deficiencies in trained teams, fragmented healthcare systems, and inefficiently distributed budget allocations.","PeriodicalId":184234,"journal":{"name":"RAS Oncology & Therapy","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125674875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Outcomes of Different Radiation Therapy Dose-splitting regimens after Radical Surgery for Early stage Breast Cancer 早期乳腺癌根治性手术后不同放射治疗剂量分割方案的疗效

RAS Oncology & Therapy Pub Date : 1900-01-01 DOI: 10.51520/2766-2586-18

K. M, Shen Wb, Diallo Fb, Camara A, Akré Acpd, T. B, Zhu Sc

{"title":"Outcomes of Different Radiation Therapy Dose-splitting regimens after Radical Surgery for Early stage Breast Cancer","authors":"K. M, Shen Wb, Diallo Fb, Camara A, Akré Acpd, T. B, Zhu Sc","doi":"10.51520/2766-2586-18","DOIUrl":"https://doi.org/10.51520/2766-2586-18","url":null,"abstract":"Objective: To investigate the outcomes of different dose-splitting radiotherapy regimens after radical or modified radical surgery for early-stage breast cancer.\u0000\u0000Material and methods: Between 2015 and 2020, 412 patients treated with radiotherapy after radical or modified radical surgery for early-stage breast cancer were allocated into 3 groups according to different dose-splitting regimens of postoperative radiotherapy. Conventional radiotherapy group157 cases, 2Gy/ fraction, once/day, 5 times/week, DT50 Gy; Alternate-day radiotherapy group 202 cases, 3 Gy/fraction, 3 times/week, DT45Gy; Fast radiotherapy group 53 cases, Days 1 and 3, 5Gy/fraction, Days 15 and 17, 6.5 Gy/fr, DT23Gy. Overall, 318 cases were treated with chemotherapy and/or hormone therapy. For the whole group, the 5-year overall and disease-free survival rates were 87.4% and 89.6% respectively. The 5-year disease-free survival rates for the Conventional radiotherapy group, the Alternate-day radiotherapy group, and the Fast radiotherapy group were 90.8%, 86.5%, and 84.6% (P=0.13).The locoregional recurrence rates were 7.0%, 9.9 and 5.7 respectively. There was no significant difference between the three groups in terms of local control.\u0000\u0000Conclusion: With similar 5-year disease-free-survival rates, and the same efficacy, Alternate-day radiotherapy has the advantage of giving fewer fractions, which is suitable for a unit with limited resources. Fast radiotherapy shortens the duration of the treatment, and its efficacy and toxic effects deserve further study.","PeriodicalId":184234,"journal":{"name":"RAS Oncology & Therapy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115707604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RAS Oncology &amp; Therapy最新文献

RAS Oncology & Therapy最新文献